Preclinical evaluation of gold-DTDTPA nanoparticles as theranostic agents in prostate cancer radiotherapy - Institut Lumière Matière Accéder directement au contenu
Article Dans Une Revue Nanomedicine Année : 2016

Preclinical evaluation of gold-DTDTPA nanoparticles as theranostic agents in prostate cancer radiotherapy

Résumé

Aim: Gold nanoparticles have attracted significant interest in cancer diagnosis and treatment. Herein, we evaluated the theranostic potential of dithiolated diethylenetriamine pentaacetic acid (DTDTPA) conjugated AuNPs (Au@DTDTPA) for CT-contrast enhancement and radiosensitization in prostate cancer. Materials & methods: In vitro assays determined Au@DTDTPA uptake, cytotoxicity, radiosensitizing potential and DNA damage profiles. Human PC3 xenograft tumor models were used to determine CT enhancement and radiation modulating effects in vivo. Results: Cells exposed to nanoparticles and radiation observed significant additional reduction in survival compared with radiation only. Au@DTDTPA produced a CT enhancement of 10% and a significant extension in tumor growth delay from 16.9 days to 38.3 compared with radiation only. Conclusion: This study demonstrates the potential of Au@DTDTPA to enhance CT-image contrast and simultaneously increases the radiosensitivity of prostate tumors.
Fichier principal
Vignette du fichier
hal-01405741.pdf (2.35 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

hal-01405741 , version 1 (05-12-2016)

Identifiants

Citer

Karl Butterworth, James Nicol, Mihaela Ghita, Soraia Rosa, Pankaj Chaudhary, et al.. Preclinical evaluation of gold-DTDTPA nanoparticles as theranostic agents in prostate cancer radiotherapy. Nanomedicine, 2016, 11 (16), pp.2035-2047. ⟨10.2217/nnm-2016-0062⟩. ⟨hal-01405741⟩
167 Consultations
234 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More